Enrollment complete in HEALEY Phase 2/3 trial arm of SLS-005
Seelos Therapeutics has finished enrolling patients in its Phase 2/3 clinical trial of SLS-005 to treat amyotrophic…
Articles by Teresa Carvalho, MS
Enrollment complete in new trial of approved ALS therapy Relyvrio
A large Phase 3 trial designed to confirm the safety and efficacy of the approved therapy Relyvrio (sodium phenylbutyrate…
uniQure Acquires Rights to Develop APB-102
uniQure has entered an agreement to acquire the full rights to Apic Bio‘s investigational gene therapy APB-102, which is…
Amylyx Selects Neopharm to Market AMX0035 for ALS in Middle East
Neopharm has acquired exclusive rights to commercialize AMX0035 (sodium phenylbutyrate and taurursodiol) in Israel, Gaza, the West Bank,…
Radicava Oral Suspension Favored for Reimbursement in Canada
An oral suspension form of Radicava (edaravone), an approved treatment of amyotrophic lateral sclerosis (ALS), was favored for patient…
Health Canada, Needing More Data on Masitinib for ALS, Halts Review
Health Canada asked more information regarding masitinib as a potential add-on therapy for amyotrophic lateral sclerosis (ALS)Â before continuing…
Radicava Oral Suspension Approved in Canada to Treat ALS
Radicava Oral Suspension, an oral formulation of edaravone, has been approved in Canada for treating amyotrophic lateral sclerosis (ALS).
Increased Levels of Proteins in CSF Linked to Poor Prognosis in ALS
High total protein levels in the cerebrospinal fluid (CSF) — the liquid that surrounds the brain and spinal cord —…
Funding Expands Access to SLS-005 Via Compassionate Use
Seelos Therapeutics is planning to launch an expanded access program (EAP) that gives people with amyotrophic lateral sclerosis…
Cytokinetics Launches 5th Annual Patient Advocacy Grant Program
Cytokinetics has launched its fifth annual Communications Grant Program to support patient advocacy groups working with amyotrophic lateral…